Literature DB >> 12064818

Local gastric and serum concentrations of rebamipide following oral ingestion in healthy volunteers.

Taiji Akamatsu1, Naoshi Nakamura, Naoyuki Furuya, Toshiki Shimizu, Akira Gotou, Kendo Kiyosawa, Tsutomu Katsuyama, Takahiko Osumi, Yukihiro Hirao, Gohatiro Miyamoto.   

Abstract

The purpose of this study was to investigate whether sufficient concentrations of rebamipide (COR) are actually present in the stomach after its oral ingestion at an ordinary clinical dose. Twenty healthy volunteers (total 42 man-days) participated in the study. After ingestion of 100, 200, or 300 mg of rebamipide, endoscopy was performed at 1, 2, 4, and 6 hr, and gastric mucosa or gastric mucus was taken from the antrum. Venous blood samples were taken simultaneously. Samples were analyzed by high-performance liquid chromatography. The COR in the gastric mucosa and gastric mucus did not depend on the original amount ingested. After ingestion of rebamipide, each COR was higher than 10(-4) M (37 microg/g tissue) at 1 or 2 hr. On the other hand, the COR in serum did depend on the amount ingested and was lower than 10(-6) M (0.37 microg/ml) at every time tested. These results suggest that the COR in the stomach exceeds the levels that are needed for various antiulcer actions and that the rebamipide levels present in the gastric mucosa and gastric mucus result from local penetration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064818     DOI: 10.1023/a:1015347219999

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Rebamipide protects against activation of neutrophils by Helicobacter pylori.

Authors:  N Yoshida; T Yoshikawa; S Iinuma; M Arai; S Takenaka; K Sakamoto; T Miyajima; Y Nakamura; N Yagi; Y Naito; F Mukai; M Kondo
Journal:  Dig Dis Sci       Date:  1996-06       Impact factor: 3.199

2.  High-performance liquid chromatographic procedure for the determination of a new anti-gastric ulcer agent, 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propioni c acid, in human plasma and urine.

Authors:  Y Shioya; T Shimizu
Journal:  J Chromatogr       Date:  1988-12-29

3.  Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats.

Authors:  K Murakami; K Okajima; M Uchiba; N Harada; M Johno; H Okabe; K Takatsuki
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

4.  Helicobacter pylori and the surface mucous gel layer of the human stomach.

Authors:  T Shimizu; T Akamatsu; A Sugiyama; H Ota; T Katsuyama
Journal:  Helicobacter       Date:  1996-12       Impact factor: 5.753

5.  Local gastric and serum amoxicillin concentrations after different oral application forms.

Authors:  M P Cooreman; P Krausgrill; K J Hengels
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

6.  Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance.

Authors:  T Yoshikawa; Y Naito; T Tanigawa; M Kondo
Journal:  Arzneimittelforschung       Date:  1993-03

7.  Effects of rebamipide in combination with lansoprazole and amoxicillin on Helicobacter pylori-infected gastric ulcer patients.

Authors:  M Kato; M Asaka; T Sugiyama; M Kudo; K Nishikawa; M Sukegawa; K Hokari; M Katagiri; F Sato; H Kagaya; H Takeda
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

8.  Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines.

Authors:  M Aihara; A Azuma; H Takizawa; D Tsuchimoto; Y Funakoshi; Y Shindo; Y Ohmoto; K Imagawa; M Kikuchi; N Mukaida; K Matsushima
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

Review 9.  Modification of Helicobacter pylori adhesion to human gastric epithelial cells by antiadhesion agents.

Authors:  S Hayashi; T Sugiyama; M Asaka; K Yokota; K Oguma; Y Hirai
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

10.  Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer.

Authors:  H Nebiki; K Higuchi; T Arakawa; K Ando; T Uchida; H Ito; S Harihara; T Kuroki; K Kobayashi
Journal:  Dig Dis Sci       Date:  1998-09       Impact factor: 3.199

View more
  6 in total

1.  Population pharmacokinetic analysis of rebamipide in healthy Korean subjects with the characterization of atypical complex absorption kinetics.

Authors:  Lien Ngo; Hee-Doo Yoo; Phuong Tran; Hea-Young Cho; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-03-18       Impact factor: 2.745

2.  Small bowel tissue concentration of rebamipide: study of two dosages in healthy subjects.

Authors:  Taiji Akamatsu; Tadanobu Nagaya; Shinya Ichikawa; Takamori Sudo; Ryutaro Takeda; Kazuhiro Takenaka; Ryo Kodama; Tetsuya Ito; Norikazu Arakura; Eiji Tanaka
Journal:  J Clin Biochem Nutr       Date:  2010-10-29       Impact factor: 3.114

3.  Gastric Helicobacter infection inhibits development of oral tolerance to food antigens in mice.

Authors:  Tamara Matysiak-Budnik; Guillaume van Niel; Francis Mégraud; Kathryn Mayo; Claudia Bevilacqua; Valérie Gaboriau-Routhiau; Marie-Christiane Moreau; Martine Heyman
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

4.  Rebampide enema therapy as a treatment for patients with chronic radiation proctitis: initial treatment or when other methods of conservative management have failed.

Authors:  Tae Oh Kim; Geun Am Song; Sun Mi Lee; Gwang Ha Kim; Jeong Heo; Dae Hwan Kang; Mong Cho
Journal:  Int J Colorectal Dis       Date:  2008-03-08       Impact factor: 2.571

5.  Rebamipide inhibits gastric cancer cell growth.

Authors:  Tetsuya Tanigawa; Rama Pai; Tetsuo Arakawa; Andrzej S Tarnawski
Journal:  Dig Dis Sci       Date:  2006-12-14       Impact factor: 3.487

6.  A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage.

Authors:  Toshio Watanabe; Toshihisa Takeuchi; Osamu Handa; Yasuhisa Sakata; Tetsuya Tanigawa; Masatsugu Shiba; Yuji Naito; Kazuhide Higuchi; Kazuma Fujimoto; Toshikazu Yoshikawa; Tetsuo Arakawa
Journal:  PLoS One       Date:  2015-04-15       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.